# US 2024/0409622 A1 · Optimized crosslinkers for trapping a target on a substrate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0409622 A1
- Document ID: US20240409622A1
- Status: Published application
- Kind: A1
- Application number: 18/809,679
- Filed: 2024-08-20
- Published: 2024-12-12
- Earliest claimed: 2015-11-13
- Assignees: The University of North Carolina at Chapel Hill
- Applicants: The University of North Carolina at Chapel Hill
- Inventors: Samuel Lai; M. Gregory Forest; Christine Henry; Timothy Wessler; Alexander Chen; Jennifer Schiller; Jay Newby
- Web page: https://patentgrep.com/patent/US20240409622A1

## CPC

- C07K 16/1235: Salmonella (G)
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C07K 16/087: Herpes simplex virus
- C07K 16/114: Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- G01N 33/54346: {Nanoparticles}
- G01N 33/557: using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
- G01N 33/56983: {Viruses}
- G01N 33/6854: {Immunoglobulins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- G01N 2333/16: HIV-1, HIV-2
- G01N 2333/4725: Mucins, e.g. human intestinal mucin
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contraception. The methods may be used to trap or separate particles and other substances. The subject matter further relates to methods of identifying and preparing optimal crosslinkers and methods for manipulating targets of interest.

## Claims

### Claim 1

A method for providing contraception, said method comprising: altering a binding affinity of a crosslinker to a vaginal mucosal extracellular matrix substrate to form a pool of candidate crosslinkers that binds to both the vaginal mucosal extracellular matrix substrate and to sperm; selecting an altered crosslinker that associates with the vaginal mucosal extracellular matrix substrate between 20% to less than 95% of the time, has a rate of binding to sperm that is greater than about 1×104 M−1s−1, and that has a diffusion coefficient that is between 20% to 99% less than a diffusion coefficient of the altered crosslinker in water from the pool of candidate crosslinkers; and providing the altered crosslinker for delivery to a subject's vaginal mucosal extracellular matrix, wherein the crosslinker comprises an antibody or portion of an antibody that binds to the sperm.

### Claim 2 (depends on 1)

The method of claim 1, wherein altering comprises selecting for the altered crosslinker from a pool of candidate crosslinkers that have been altered.

### Claim 3 (depends on 1)

The method of claim 1, wherein altering the binding affinity of the crosslinker to the extracellular matrix comprises chemically modifying the crosslinker.

### Claim 4 (depends on 3)

The method of claim 3, wherein chemically modifying the crosslinker comprises biotinylating the crosslinker.

### Claim 5 (depends on 3)

The method of claim 3, wherein chemically modifying the crosslinker comprises covalently linking a scaffold to the crosslinker.

### Claim 6 (depends on 1)

The method of claim 1, further comprising formulating the altered crosslinker as a vaginal: gel, paste, suppository, douche, ovule, foam, film, spray, ointment, pessary, capsule, tablet, jelly, cream, milk, dispersion, liposomes, powder/talc, suspension, solution, emulsion, microemulsion, nanoemulsion, and/or liquid.

### Claim 7 (depends on 1)

The method of claim 1, further comprising administering the altered crosslinker to the subject.

### Claim 8 (depends on 1)

The method of claim 1, wherein the crosslinker is an antibody or an antibody fragment or derivative.

### Claim 9 (depends on 8)

The method of claim 8, wherein the antibody is selected from IgG, IgA, IgM, or a fragment or derivative thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein at least one Fc region is preserved.

### Claim 11

A method for contraception, said method comprising: forming an altered crosslinker that has a binding affinity to an extracellular matrix, wherein the crosslinker is an antibody or antibody fragment that binds to both extracellular matrix substrate and to a sperm, wherein the altered crosslinker has been selected to associate with the extracellular matrix between 20% to less than 95% of the time, has a rate of binding to the sperm greater than about 1×104 M−1s−1, and has a diffusion coefficient that is between 20% to 99% less than a diffusion coefficient of the altered crosslinker in water; compounding the altered crosslinker for administration to a subject's vagina or uterus, wherein the altered crosslinker is formulated as one or more of a: gel, paste, suppository, douche, ovule, foam, film, spray, ointment, pessary, capsule, tablet, jelly, cream, milk, dispersion, liposomes, powder/talc, suspension, solution, emulsion, microemulsion, nanoemulsion, and/or liquid.

### Claim 12 (depends on 11)

The method of claim 11, further comprising and administering the altered crosslinker to the subject.

### Claim 13 (depends on 11)

The method of claim 11, wherein the binding affinity of the crosslinker to the extracellular matrix has been altered by chemically modifying the crosslinker.

### Claim 14 (depends on 13)

The method of claim 13, wherein chemically modifying the crosslinker comprises biotinylating the crosslinker.

### Claim 15 (depends on 13)

The method of claim 13, wherein chemically modifying the crosslinker comprises covalently linking a scaffold to the crosslinker.

### Claim 16 (depends on 13)

The method of claim 13, wherein the antibody is selected from IgG, IgA, IgM, or a fragment or derivative thereof.

### Claim 17 (depends on 11)

The method of claim 11, wherein the crosslinker is an antibody or an antibody fragment or derivative.

### Claim 18 (depends on 17)

The method of claim 17, wherein the antibody is selected from IgG, IgA, IgM, or a fragment or derivative thereof.

### Claim 19 (depends on 11)

The method of claim 11, wherein at least one Fc region is preserved.
